Cell & Gene Collaborative Blog

41. Time Well-Spent: Embracing Opportunity Costs In Gene Therapy Manufacturing 4/11/2022

    It goes without saying that “taking time” to get a solid process in place is a best practice. But what I particularly appreciated about my conversation with Tenaya CTO's Kee-Hong Kim was how his own experiences and perspectives helped define what exactly “time well spent” means in the CGT development process. 

42. ARW's C&G Manufacturing Must-Reads (GIANT RODENT! Edition) 4/8/2022

    Day-in and day-out, I write, read, listen to, and watch as much content as I can about C&G therapy manufacturing, in particular, and/or other C&G industry-related topics that you should at least be aware of in the manufacturing facility. Every two weeks, I compile the articles and industry updates I think are most worthy of your time into an unconventional newsletter format (below) and send them out via email. But inboxes can be shifty places. (Cue George Carlin on “Losing Things.”)

43. Show Me The Money! A Closer Look At COGS In Gene Therapy Manufacturing 4/6/2022

    It’s almost inevitable that any conversation about manufacturing will be filled with references to “Time” and “Money,” and my conversation with Tenaya CTO, Kee-Hong Kim was no exception. But while these words can be dangerously vague, Kim’s experience added some valuable context into how he approaches these two resources in his role — starting first with “money.”

44. Your C&G Manufacturing Must-Reads (Philly Cheesesteak Edition!) 3/25/2022

    Here’s a “permanent” copy of my C&G Manufacturing Must-Reads newsletter that was delivered on March 24, which just happened to be National Cheesesteak Day. Ergo, this is the “Philly Cheesesteak edition” of your manufacturing must-reads, in honor of our many friends in “Cellicon Valley”/Philadelphia.

45. Your C&G Manufacturing Must-Reads (Super Mario Edition!) 3/11/2022

    This is a “permanent” copy of my C&G Manufacturing Must-Reads newsletter that was delivered on March 10. As March 10 is also known as Super Mario Day (Mar10), this Manufacturing Must-Reads has a Super Mario theme. 

46. From “Wild West” To “Rainforest”: Cell & Gene Manufacturing Ecosystem Embraces Symbiosis 2/28/2022

    We often affectionately refer to the CGT manufacturing sector as “The Wild West.” However, I’m also starting to see a subtle reformation happening — one that takes us beyond the barren desert full of dueling cowboys and heat-crazed goldminers to that of a lush, productive, and symbiotic rainforest.

47. Your C&G Manufacturing Must-Reads (Mixologist Edition!) 2/25/2022

    Day-in and day-out, I write, read, listen to, and watch as much content as I can about C&G therapy manufacturing, in particular, and/or other C&G industry-related topics that you should at least be aware of in the manufacturing facility. Every two weeks, I compile the articles and industry updates I think are most worthy of your time into an unconventional newsletter format (below) and send them out via email. But inboxes can be shifty places. (Cue George Carlin on “Losing Things.”)

48. Lightning-Fast CMC Meets Incremental Innovation in Cell & Gene Therapy Manufacturing 2/24/2022

    I’ve heard it said that cell and gene therapy companies shouldn’t “let the perfect be the enemy of the good.” My conversation with Wugen’s VP of CMC, Ken Chrobak, was a fantastic example of how such a best practice can be translated into an actual CGT manufacturing program.

49. Beyond Cell Expansion: Building A Commercial CGT Manufacturing Framework 2/22/2022

    In the third of this four-part series, I transitioned my conversation with Ken Chrobak, Wugen’s VP of CMC, from the nuances of cell culture to the steps he and his team are taking to establish a consistent manufacturing framework that can span oceans and continents.

50. Zen & The Art Of Allogeneic NK Cell Therapy Manufacturing 2/17/2022

    Though my previous article with Ken Chrobak, VP of CMC for Wugen, highlighted which learnings could be taken from the autologous manufacturing space and applied to allogeneic therapies, we can’t overlook the layers of complexity that the cell type inherently throws into the manufacturing mix.